普门科技收盘上涨1.24%，滚动市盈率19.22倍，总市值56.09亿元

Group 1 - The core business of the company includes research, manufacturing, global sales, and services of in vitro diagnostics, clinical medicine, skin aesthetics, and consumer health products [2] - The company achieved a revenue of 215 million yuan in Q1 2025, representing a year-on-year decrease of 29.69%, and a net profit of 53.68 million yuan, down 49.93% year-on-year, with a gross profit margin of 64.97% [2] - The company has received multiple awards, including the "Smart Health Elderly Care Application Pilot Demonstration Enterprise" honor and the "2023 China Corrosion and Protection Society Science and Technology Award" [2] Group 2 - The company's current price-to-earnings (PE) ratio is 19.22, which is significantly lower than the industry average of 51.58 and the industry median of 37.46 [3] - The total market capitalization of the company is 5.609 billion yuan [1] - As of Q1 2025, there are 7 institutions holding shares in the company, with a total holding of 39.11 million shares valued at 588 million yuan [1]